Taft partners Stephen Auten and Andrew Alul will speak at the American Conference Institute’s (ACI) Paragraph IV Disputes Conference on April 27-28 in New York. Auten’s presentation is titled “Exploring the Utilization of Reissue Applications to Cure Invalidity Findings at the PTAB and District Courts.” Alul will moderate a session titled “Limelight v. Akamai: Assessing Its Impact on Method of Treatment Patents and Section viii Label Carve Outs.”
The event is known as the pharmaceutical industry's leading forum on Hatch-Waxman litigation. Taft will sponsor the breakfast on April 27. To register or learn more about this event, please click here.
Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has nearly 6,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Alul focuses his practice primarily on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the U.S. Food and Drug Administration (FDA). He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.